<?xml version='1.0' encoding='utf-8'?>
<document id="8866337"><sentence text="Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver."><entity charOffset="0-10" id="DDI-PubMed.8866337.s1.e0" text="Mefloquine" /><entity charOffset="36-48" id="DDI-PubMed.8866337.s1.e1" text="halofantrine" /><pair ddi="false" e1="DDI-PubMed.8866337.s1.e0" e2="DDI-PubMed.8866337.s1.e0" /><pair ddi="false" e1="DDI-PubMed.8866337.s1.e0" e2="DDI-PubMed.8866337.s1.e1" /></sentence><sentence text="Halofantrine and mefloquine are antimalarial drugs used in the treatment of malaria, including that caused by chloroquine-resistant Plasmodium falciparum"><entity charOffset="0-12" id="DDI-PubMed.8866337.s2.e0" text="Halofantrine" /><entity charOffset="17-27" id="DDI-PubMed.8866337.s2.e1" text="mefloquine" /><entity charOffset="110-121" id="DDI-PubMed.8866337.s2.e2" text="chloroquine" /><pair ddi="false" e1="DDI-PubMed.8866337.s2.e0" e2="DDI-PubMed.8866337.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8866337.s2.e0" e2="DDI-PubMed.8866337.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8866337.s2.e0" e2="DDI-PubMed.8866337.s2.e2" /><pair ddi="false" e1="DDI-PubMed.8866337.s2.e1" e2="DDI-PubMed.8866337.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8866337.s2.e1" e2="DDI-PubMed.8866337.s2.e2" /></sentence><sentence text=" Reports of drug-associated adverse reactions, including sudden death in one patient, have prompted concerns over the safety of halofantrine and the potential for drug-drug interactions"><entity charOffset="128-140" id="DDI-PubMed.8866337.s3.e0" text="halofantrine" /></sentence><sentence text=" We used the isolated perfused rat liver (IPRL) model to investigate a possible hepatic metabolic or pharmacokinetic drug-drug interaction between halofantrine and mefloquine"><entity charOffset="147-159" id="DDI-PubMed.8866337.s4.e0" text="halofantrine" /><entity charOffset="164-174" id="DDI-PubMed.8866337.s4.e1" text="mefloquine" /><pair ddi="false" e1="DDI-PubMed.8866337.s4.e0" e2="DDI-PubMed.8866337.s4.e0" /><pair ddi="false" e1="DDI-PubMed.8866337.s4.e0" e2="DDI-PubMed.8866337.s4.e1" /></sentence><sentence text=" Pharmacokinetic parameter estimates for halofantrine in the IPRL reflected the pattern seen in in-vivo studies with doses comparable with clinical doses"><entity charOffset="41-53" id="DDI-PubMed.8866337.s5.e0" text="halofantrine" /></sentence><sentence text=" Halofantrine parameter estimates (mean +/- s"><entity charOffset="1-13" id="DDI-PubMed.8866337.s6.e0" text="Halofantrine" /></sentence><sentence text="d" /><sentence text=") were: volume of distribution (Vd), 7" /><sentence text="53 +/- 1" /><sentence text="45 mL (g liver)-1; clearance (CL), 0" /><sentence text="11 +/- 0" /><sentence text="07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14" /><sentence text="62 +/- 2" /><sentence text="38 min; terminal half-life (terminal t1/2), 138" /><sentence text="7 +/- 178" /><sentence text="8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0" /><sentence text="0135 +/- 0" /><sentence text="012 min-1" /><sentence text=" Prior dosing with mefloquine did not affect halofantrine perfusate pharmacokinetic parameter estimates of Vd, Ke, initial and terminal t1/2 (P &gt; 0"><entity charOffset="19-29" id="DDI-PubMed.8866337.s19.e0" text="mefloquine" /></sentence><sentence text="05)" /><sentence text=" A single dose, short term (4-6 h) interaction showed significant changes in the perfusate clearance of halofantrine in mefloquine-pretreated livers using higher doses of halofantrine"><entity charOffset="104-116" id="DDI-PubMed.8866337.s21.e0" text="halofantrine" /><entity charOffset="120-130" id="DDI-PubMed.8866337.s21.e1" text="mefloquine" /><entity charOffset="171-183" id="DDI-PubMed.8866337.s21.e2" text="halofantrine" /><pair ddi="false" e1="DDI-PubMed.8866337.s21.e0" e2="DDI-PubMed.8866337.s21.e0" /><pair ddi="false" e1="DDI-PubMed.8866337.s21.e0" e2="DDI-PubMed.8866337.s21.e1" /><pair ddi="false" e1="DDI-PubMed.8866337.s21.e0" e2="DDI-PubMed.8866337.s21.e2" /><pair ddi="false" e1="DDI-PubMed.8866337.s21.e1" e2="DDI-PubMed.8866337.s21.e1" /><pair ddi="false" e1="DDI-PubMed.8866337.s21.e1" e2="DDI-PubMed.8866337.s21.e2" /></sentence><sentence text=" Substantial changes were seen in bile production (P &lt; 0" /><sentence text="05) and biliary clearance (P &lt; 0" /><sentence text="05) of halofantrine in mefloquine-pretreated livers"><entity charOffset="7-19" id="DDI-PubMed.8866337.s24.e0" text="halofantrine" /><entity charOffset="23-33" id="DDI-PubMed.8866337.s24.e1" text="mefloquine" /><pair ddi="false" e1="DDI-PubMed.8866337.s24.e0" e2="DDI-PubMed.8866337.s24.e0" /><pair ddi="false" e1="DDI-PubMed.8866337.s24.e0" e2="DDI-PubMed.8866337.s24.e1" /></sentence><sentence text=" These findings may have clinical implications in models utilizing multiple drug dosages or in patients with severe malaria who have disease-related cholestasis" /><sentence text="" /></document>